Investors
Press Releases
Press releases issued by Palatin are accessible below. These press releases contain additional information about our business, clinical trial developments, research and development activities, financial achievements, and strategic partnerships.
Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate Update
September 28, 2023
Palatin to Report Fourth Quarter and Fiscal Year End 2023 Results; Teleconference and Webcast to be held on September 28, 2023
September 22, 2023
Palatin to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 7, 2023
Palatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye Disease
September 7, 2023
Palatin Announces Direct-to-Consumer Telehealth Partnership with UpScriptHealth™ for Vyleesi®
August 7, 2023
Palatin Announces Preliminary Fourth Quarter Fiscal 2023 Vyleesi® Product Revenue Results
July 11, 2023
Palatin Presents Preclinical Diabetic Nephropathy Data at the International Podocyte Conference
May 30, 2023
Palatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
May 16, 2023
Palatin to Report Third Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on May 16, 2023
May 11, 2023
Palatin Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference
May 9, 2023
Palatin Invites Investors to Listen to Replay of the PL9643 Dry Eye Disease Key Opinion Leader Webinar
May 8, 2023
Palatin Announces Preliminary Third Quarter Fiscal 2023 Vyleesi® Product Revenue Results
April 19, 2023
Palatin Issued Patent on Vyleesi® (Bremelanotide Injection) For Hypoactive Sexual Desire Disorder in Patients With Controlled Hypertension
February 28, 2023
Palatin Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
February 15, 2023
Palatin to Report Second Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on February 15, 2023
February 10, 2023
Palatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease
January 19, 2023
Palatin Receives $4.7 Million of Non-Dilutive Funding
January 18, 2023